EyePoint (EYPT) Cash from Operations (2010 - 2026)
EyePoint (EYPT) posted Cash from Operations of 80549000.0 for Q1 2026, down 23.83% sequentially from 65047000.0 in Q4 2025, and down 51.64% YoY from 166547151.92 in Q1 2025.
Powered by 
Analysis
EyePoint (EYPT) Cash from Operations (2010 - 2026) Analysis & Trends
EyePoint has reported Cash from Operations for 17 years, with the latest figure at 80549000.0 in Q1 2026.
- Quarterly Cash from Operations fell 51.64% year-over-year to 80549000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 267539000.0 (down 80.56% YoY) and the FY2025 annual result came in at 240110000.0, down 90.22% from the prior year.
- Cash from Operations eased to 80549000.0 in Q1 2026 per EYPT's latest filing, from 65047000.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 57023000.0 in Q2 2023 and troughed at 80549000.0 in Q1 2026.
- A 5-year average of 30000882.35 and a median of 23109000.0 in 2023 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2023 and 2025: Cash from Operations surged 398.19% in 2023, then sank 210.18% in 2025.
- Over 5 years, Cash from Operations stood at 12588000.0 in 2022, then tumbled by 83.58% to 23109000.0 in 2023, then plunged by 55.13% to 35849000.0 in 2024, then plunged by 81.45% to 65047000.0 in 2025, then declined by 23.83% to 80549000.0 in 2026.
- According to Business Quant data, Cash from Operations over the past three periods registered 80549000.0, 65047000.0, and 59354000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -526.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -387.32 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 462.82 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 326.72 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 728.46 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -88.83 Mn |
| 10 | EyePoint | 398.53 Mn | 218.06 Mn | 507,000.00 | -62.35 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -62.35 Mn |
| Mar 31, 2026 | -80.55 Mn |
| Dec 31, 2025 | -65.05 Mn |
| Sep 30, 2025 | -59.35 Mn |
| Jun 30, 2025 | -62.59 Mn |
| Mar 31, 2025 | -53.12 Mn |
| Dec 31, 2024 | -35.85 Mn |
| Sep 30, 2024 | -39.03 Mn |
| Jun 30, 2024 | -20.18 Mn |
| Mar 31, 2024 | -31.17 Mn |
| Dec 31, 2023 | -23.11 Mn |
| Sep 30, 2023 | -15.20 Mn |
| Jun 30, 2023 | 57.02 Mn |
| Mar 31, 2023 | -16.84 Mn |
| Dec 31, 2022 | -12.59 Mn |
| Sep 30, 2022 | -13.14 Mn |
| Jun 30, 2022 | -19.12 Mn |
| Mar 31, 2022 | -20.16 Mn |
| Dec 31, 2021 | -16.67 Mn |
| Sep 30, 2021 | -7.79 Mn |